Table 1 Baseline characteristics for 140 patients
All patients (n = 140) | |
|---|---|
Age | 72 (67–78) |
PSA (µg/L) | 86 (12–258) |
Hemoglobin (g/dL) | 11.9 (10.4–13.2) |
White blood cells (109/L) | 6.4 (5.0–7.8) |
Platelets (109/L) | 238 (188–286) |
eGFR (mL/min/1.73 m2) | 81.8 (68.0–93.7) |
Alkaline phosphatase (U/L) | 93 (67–200) |
LDH (U/L) | 240 (205–303) |
Gleason score* | |
< 8 | 42 (34) |
≥ 8 | 82 (66) |
ECOG performance status | |
0 | 42 (30) |
1 | 81 (58) |
2 | 17 (12) |
Sites of metastases | |
Bone | 125 (89) |
Uni-/oligo-/multifocal | 48 (34) |
Disseminated/diffuse | 77 (55) |
Lymph nodes | 125 (89) |
Visceral | 33 (24) |
Previous mCRPC therapies | |
Abiraterone | 87 (62) |
Enzalutamide | 75 (54) |
223Radium-dichloride | 45 (32) |
Docetaxel | 70 (50) |
Cabazitaxel | 27 (19) |
Other chemotherapies† | 7 (5) |
EBRT (bone metastases) | 49 (35) |